Orforglipron Results Timeline: What Studies Measured, and When

Questions about "how long orforglipron takes to work" usually assume that trials tracked change continuously. They did not. Clinical studies of orforglipron, an oral non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, collected data at pre-specified visits, and the published abstracts report change from baseline at those visits only. Understanding the timeline therefore means understanding the trial calendar: when investigators measured, what they measured, and what the numbers at each point described across a whole randomised group rather than any one person.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or health decision. Nothing here describes a protocol, schedule or dose for personal use.

What a "results timeline" means in trial terms

In drug trials, a timeline is a set of visit windows attached to endpoints. A primary endpoint is fixed at one timepoint — for example, percentage change in body weight at a defined week — and secondary endpoints may be captured earlier or later. Group averages at each visit are least-squares means adjusted for the trial model, not individual trajectories. A 2025 systematic review of emerging obesity pharmacotherapies placed orforglipron among the oral agents being evaluated in this endpoint-driven framework (PMID 39952695), and a 2026 network meta-analysis of drugs for adults with overweight or obesity compared agents on such trial-defined endpoints rather than on time-to-effect (PMID 42419792).

The earliest human measurements: phase 1, days to weeks

The first human timeline for orforglipron came from a phase 1a, blinded, placebo-controlled, randomised single- and multiple-ascending-dose study in healthy participants, in which researchers measured pharmacokinetics, safety and tolerability after single doses and across a multiple-ascending-dose period (PMID 37344954). That study reported pharmacokinetic characteristics consistent with once-daily oral administration and gastrointestinal events as the most common adverse findings (PMID 37344954). Those are exposure and tolerability measurements on a scale of hours to a few weeks — not efficacy outcomes, and not a statement about when weight or glucose changes appear.

Preclinical timelines, clearly labelled

Before human dosing, the pharmacological groundwork was laid in laboratory work. A 2024 Science Translational Medicine paper described the pharmacological basis for non-peptide agonism of the GLP-1 receptor by orforglipron, characterising receptor engagement and signalling behaviour that distinguish a small molecule from peptide agonists (PMID 39693407). Receptor-level events in such experiments occur over minutes to hours in cell systems, while animal-model readouts accumulate over days to weeks; these are preclinical timescales and do not translate into a human week-by-week expectation (PMID 39693407).

Weeks 1–12: the escalation window in published trials

Human trials of orforglipron used stepwise dose escalation, so the early weeks of each study were partly a titration period rather than a steady-state efficacy window. The phase 2 obesity trial evaluated once-daily doses of 12 mg, 24 mg, 36 mg and 45 mg against placebo and reported that gastrointestinal adverse events were most frequent during dose escalation (PMID 37351564). The phase 2 dose-response trial in type 2 diabetes similarly tested a range of once-daily doses up to 45 mg and reported mild-to-moderate gastrointestinal events concentrated in the escalation phase (PMID 37369232). In other words, the published abstracts describe the early weeks primarily in tolerability terms, not as an efficacy milestone.

Weeks 26 to 40: the first efficacy endpoints

The earliest published efficacy timepoints sit at roughly six to nine months.

• Week 26 in phase 2 obesity. The study reported mean percentage change in body weight from baseline at week 26 across orforglipron dose groups versus placebo, with the placebo group changing only marginally (PMID 37351564).
• Week 36 in phase 2 obesity. The same trial carried participants to week 36 and reported larger mean percentage weight reductions at that later visit than at week 26, with the highest dose group reaching roughly 14–15% and placebo close to 2% (PMID 37351564).
• Week 26 in phase 2 type 2 diabetes. Researchers reported change in glycated haemoglobin from baseline at week 26 as the primary endpoint, with reductions of approximately two percentage points at higher doses versus a small reduction on placebo, alongside body-weight reductions measured at the same visit (PMID 37369232).
• Week 40 in early type 2 diabetes. A 2025 New England Journal of Medicine trial in early type 2 diabetes reported HbA1c change at week 40 across once-daily 3 mg, 12 mg and 36 mg groups versus placebo, with body weight measured as a secondary endpoint at the same timepoint (PMID 40544435).

What these visits show collectively is a pattern common to incretin-receptor agonist trials: the difference between treatment and placebo groups reported at a later visit was larger than the difference reported at an earlier one within the same study (PMID 37351564).

Week 72: the longest published obesity dataset

The longest reported orforglipron timeline in obesity comes from a 2025 phase 3 New England Journal of Medicine trial, in which the study measured percentage change in body weight at week 72 across once-daily 6 mg, 12 mg and 36 mg groups compared with placebo, reporting approximately 12% mean reduction in the highest dose group against roughly 1% on placebo (PMID 40960239). Because week 72 was the anchor endpoint, the abstract does not resolve month-by-month trajectory; it reports where the groups stood at that visit (PMID 40960239). A 2025 commentary in Med framed this oral small-molecule result as a notable development in obesity pharmacology (PMID 41389711).

Measurement timepoints at a glance

Comparative and pooled timelines

Head-to-head data added another reference point. A multinational, multicentre, non-inferiority, open-label, randomised phase 3 trial compared once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes, with efficacy and safety assessed against a pre-specified non-inferiority margin (PMID 41765029). Pooled evidence has also been synthesised: a 2025 systematic review and meta-analysis examined efficacy and safety of orforglipron in obese adults with or without diabetes (PMID 41296780), while a living systematic review and network meta-analysis of medications for adults with type 2 diabetes situated newer agents alongside established therapies (PMID 40813122). Meta-analyses generally pool endpoint values at each trial's own reported timepoint, so they inherit the same visit structure rather than generating a finer-grained timeline (PMID 41296780).

Adverse Events Over Time: What Studies Report

Tolerability findings also carry a timing component in the published record. The phase 2 obesity trial reported that the most common adverse events were gastrointestinal — including nausea, vomiting, constipation and diarrhoea — that these were generally mild to moderate, and that they occurred mainly during the dose-escalation period (PMID 37351564). The phase 2 type 2 diabetes trial likewise reported gastrointestinal events as the most frequent, mostly mild to moderate and concentrated during escalation (PMID 37369232). In healthy participants, researchers reported gastrointestinal adverse events as the most common finding in the phase 1a single- and multiple-ascending-dose setting (PMID 37344954). The phase 3 obesity trial also reported gastrointestinal adverse events as the most common category and described treatment discontinuations attributed to adverse events (PMID 40960239), and the phase 3 early type 2 diabetes trial reported a comparable gastrointestinal profile (PMID 40544435). The 2025 meta-analysis of obese adults with or without diabetes summarised adverse-event rates pooled across trials (PMID 41296780).

What the timeline evidence does not establish

• No week-by-week guarantee. Published abstracts report group means at scheduled visits; they do not describe when any individual participant's measurements changed (PMID 40960239).
• Escalation confounds early weeks. Because doses were titrated upward, early-visit values reflect sub-target exposure as well as time, in both the obesity and diabetes phase 2 programmes (PMID 37351564, PMID 37369232).
• Limited data beyond the longest visit. The longest published obesity endpoint reported here is week 72 (PMID 40960239); durability past that horizon and after discontinuation is not addressed in that abstract.
• Population matters. Timepoints and endpoints differed between obesity trials and type 2 diabetes trials, so numbers are not interchangeable across settings (PMID 40544435).

How to read timeline claims critically

1. Identify the visit the number belongs to — week 26, 36, 40 or 72 — before comparing figures, since the same trial reported different magnitudes at different visits (PMID 37351564).
2. Check whether the comparator was placebo or an active drug, as in the open-label non-inferiority comparison with oral semaglutide (PMID 41765029).
3. Note the dose group, because the phase 3 obesity trial reported separate results for 6 mg, 12 mg and 36 mg once daily (PMID 40960239).
4. Distinguish pooled synthesis from single trials; network meta-analyses aggregate across studies with differing follow-up (PMID 42419792, PMID 40813122).

Related reading

For background on the compound's mechanism, trial programme and regulatory context, see the overview page: Orforglipron.

References

• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (The New England Journal of Medicine, 2025)
• Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (The New England Journal of Medicine, 2025)
• Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (The New England Journal of Medicine, 2023)
• Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial (Lancet, 2026)
• The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron (Science Translational Medicine, 2024)
• Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants (Diabetes, Obesity & Metabolism, 2023)
• Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study (Lancet, 2023)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis (BMJ, 2025)
• Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis (BMJ, 2026)
• One small molecule for man, one giant leap for mankind with obesity (Med, 2025)
• Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis (Endocrinology, Diabetes & Metabolism, 2025)